Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

Michael A. Weber, Stevo Julius, Sverre E. Kjeldsen, Hans R. Brunner, Steffan Ekman, Lennart Hansson, Tsushung Hua, John H. Laragh, Gordon T. McInnes, Lada Mitchell, Francis Plat, M. Anthony Schork, Beverly Smith, Alberto Zanchetti

Research output: Contribution to journalArticle

Abstract

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test whether, for the same achieved blood pressures, regimens based on valsartan or amlodipine would have differing effects on cardiovascular endpoints in high risk hypertension. But inequalities in blood pressure, favouring amlodipine, throughout the multiyear trial precluded comparison of outcomes. A technique of serial median matching, applied at 6 months when treatment adjustments intended to achieve control of blood pressure were complete, created 5006 valsartan-amlodipine patient pairs matched exactly for systolic blood pressure, age, sex, and the presence or absence of previous coronary disease, stroke, or diabetes. Subsequent combined cardiac events, myocardial infarction, stroke, and mortality were almost identical in the two cohorts, but admission to hospital for heart failure was significantly lower with valsartan. Reaching blood pressure control (systolic

Original languageEnglish
Pages (from-to)2049-2051
Number of pages3
JournalLancet
Volume363
Issue number9426
DOIs
Publication statusPublished - Jun 19 2004

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial'. Together they form a unique fingerprint.

  • Cite this

    Weber, M. A., Julius, S., Kjeldsen, S. E., Brunner, H. R., Ekman, S., Hansson, L., Hua, T., Laragh, J. H., McInnes, G. T., Mitchell, L., Plat, F., Schork, M. A., Smith, B., & Zanchetti, A. (2004). Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet, 363(9426), 2049-2051. https://doi.org/10.1016/S0140-6736(04)16456-8